Fate Therapeutics (FATE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Syra Health Corp. (SYRA) Reports Q3 EPS of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
